Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration

Arshad M KhananiSierra Eye Associates, Reno, NV, USACorrespondence[email protected]

Pages 1315-1320 | Published online: 22 Jul 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

LimLSMitchellPSeddonJMHolzFGWongTYAge-related macular degenerationLancet201237998271728173822559899
PubMed Web of Science ®Google Scholar
RosenfeldPJBrownDMHeierJSMARINA Study GroupRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
PubMed Web of Science ®Google Scholar
Novartis PharmaAGLucentis European summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdfAccessed November 2014
Google Scholar
AbouammohMSharmaSRanibizumab versus bevacizumab for the treatment of neovascular age-related macular degenerationCurr Opin Ophthalmol201122315215821483262
PubMed Web of Science ®Google Scholar
FerraraNHillanKJGerberHPNovotnyWDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNat Rev Drug Discov20043539140015136787
PubMed Web of Science ®Google Scholar
SemeraroFMorescalchiFDuseSParmeggianiFGambicortiECostagliolaCAflibercept in wet AMD: specific role and optimal useDrug Des Devel Ther20137711722
PubMed Web of Science ®Google Scholar
PapadopoulosNMartinJRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumabAngiogenesis201215217118522302382
PubMed Web of Science ®Google Scholar
Eylea® (aflibercept) Injection [Prescribing Information]New York, NYRegeneron Pharmaceuticals Inc2012
Google Scholar
Bayer PharmaAGEylea European summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002392/WC500135815.pdfAccessed November 2014
Google Scholar
StewartMWClinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on afliberceptClin Ophthalmol201261175118622973088
PubMedGoogle Scholar
GregoriNZFeuerWRosenfeldPJNovel method for analyzing Snel-len visual acuity measurementsRetina20103071046105020559157
PubMed Web of Science ®Google Scholar
HeierJSBrownDMChongVVIEW 1 and VIEW 2 Study GroupsIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
PubMed Web of Science ®Google Scholar
SinghRPSrivastavaSEhlersJPBediRSchachatAPKaiserPKA single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysisBr J Ophthalmol201498suppl 1i22i2724836866
PubMed Web of Science ®Google Scholar
BakallBFolkJCBoldtHCAflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumabAm J Ophthalmol201315611522.e123706500
PubMed Web of Science ®Google Scholar
ChoHShahCPWeberMHeierJSAflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumabBr J Ophthalmol20139781032103523766432
PubMed Web of Science ®Google Scholar
FerronePJAnwarFNaysanJEarly initial clinical experience with intravitreal aflibercept for wet age-related macular degenerationBr J Ophthalmol201498suppl 1i17i2124795335
PubMed Web of Science ®Google Scholar
HeussenFMShaoQOuyangYJoussenAMMullerBClinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degenerationGraefes Arch Clin Exp Ophthalmol2014252690991524362854
PubMed Web of Science ®Google Scholar
HoVYYehSOlsenTWShort-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitorsAm J Ophthalmol201315612328.e223664153
PubMed Web of Science ®Google Scholar
KumarNMarsigliaMMrejenSVisual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degenerationRetina20133381605161223549101
PubMed Web of Science ®Google Scholar
MessengerWBCampbellJPFaridiAInjection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degenerationBr J Ophthalmol20149891205120724795334
PubMed Web of Science ®Google Scholar
BusbeeBGHoACBrownDMHARBOR Study GroupTwelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degenerationOphthalmology201312051046105623352196
PubMed Web of Science ®Google Scholar
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupMartinDFMaguireMGRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsOphthalmology201211971388139822555112
PubMed Web of Science ®Google Scholar
AbediFWickremasingheSIslamAFInglisKMGuymerRHAnti-VEGF treatment in neovascular age-related macular degeneration. A treat-and-extend protocol over 2 yearsRetina20143481531153824637667
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date